Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Research
    • Structural Heart Disease
    • TAVR
    • Therapies
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe

Search form

Home
News You Need to Know Today
Breaking News: AstraZeneca COVID-19 vaccine associated with risk of rare, potentially fatal blood clots
Wednesday, April 7, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Breaking News

AstraZeneca COVID-19 vaccine associated with risk of rare, potentially fatal blood clots

These blood clots have been responsible for a total of 18 deaths. Experts have continued to emphasize that the benefits of vaccination still outweigh the risks.

READ MORE >
Vaccination
Share on Twitter Share on Facebook Share on Linkedin

AstraZeneca COVID-19 vaccine associated with risk of rare, potentially fatal blood clots

Share on Twitter Share on Facebook Share on Linkedin
Vaccination
These blood clots have been responsible for a total of 18 deaths. Experts have continued to emphasize that the benefits of vaccination still outweigh the risks.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Week in Review: Patient injuries lead to recall | SAVR bests TAVR | Key takeaways from AHA 2024 | FDA clears AI screening tool
Week in Review: Payment cuts & beyond | Isotope shortage may be over | TAVR valves after 5 years | Fraud lands doc in prison
Week in Review: Higher payments for CCTA | Lessons from EARLY TAVR | FDA approves another PFA system
October's Top Stories: FDA’s tirzepatide decision | Compensation rises | TAVR survival dips | Why are there so many recalls?
Week in Review: FDA approves all-in-one PFA system | TAVR for asymptomatic AS | Cardiologist gets life in prison
test newsletter extra space?
Week in Review: New CPT code for AI software | Why are device recalls so common? | Heart surgeon compensation rises

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Sitemap
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • AI in Healthcare
  • Cardiovascular Business
  • HealthExec
  • Health Imaging
  • Radiology Business
 
© 2024 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme